Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma
Background: Infantile hemangioma (IH) in most cases can be a self-limited condition; however, it may be ulcerated, infected, causing organ function disability and even death. Vascular endothelial growth factor (VEGF) has a role in IH. Bevacizumab is a monoclonal antibody against VEGF-A. Objectives:...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-04-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2019.1590521 |
| _version_ | 1797683679461376000 |
|---|---|
| author | Hanan H. Sabry Neveen E. Sorour Essam M. Akl |
| author_facet | Hanan H. Sabry Neveen E. Sorour Essam M. Akl |
| author_sort | Hanan H. Sabry |
| collection | DOAJ |
| description | Background: Infantile hemangioma (IH) in most cases can be a self-limited condition; however, it may be ulcerated, infected, causing organ function disability and even death. Vascular endothelial growth factor (VEGF) has a role in IH. Bevacizumab is a monoclonal antibody against VEGF-A. Objectives: We aimed to evaluate and compare the efficacy of intralesional injection of bevacizumab versus triamcinolone acetonide (TAC) in IH. Methods: Thirty patients with IH were included in this study, divided into two equal groups, and treated with intralesional injection; the first group by bevacizumab and the second group by TAC. The injections in both groups were given every 4 weeks for six sessions. Assessment of the clinical response was done by the hemangioma activity score (HAS) and visual analog scale (VAS). Results: Both treatment modalities gave similar initial improvement after three sessions. However, with continuing injection sessions, bevacizumab reached a response’s plateau and TAC gave better significant results after six injection sessions reading both HAS (p = .0017) and VAS (p ≤.001). Conclusion: Both intralesional injection of bevacizumab and TAC were safe and effective treatments in early proliferative IH after three sessions, however, TAC injection was significantly better than bevacizumab after six sessions. |
| first_indexed | 2024-03-12T00:17:40Z |
| format | Article |
| id | doaj.art-0cd6a1ecc8c946178f7392c746088d91 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:17:40Z |
| publishDate | 2020-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-0cd6a1ecc8c946178f7392c746088d912023-09-15T14:08:34ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532020-04-0131327928410.1080/09546634.2019.15905211590521Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangiomaHanan H. Sabry0Neveen E. Sorour1Essam M. Akl2Benha UniversityBenha UniversityBenha UniversityBackground: Infantile hemangioma (IH) in most cases can be a self-limited condition; however, it may be ulcerated, infected, causing organ function disability and even death. Vascular endothelial growth factor (VEGF) has a role in IH. Bevacizumab is a monoclonal antibody against VEGF-A. Objectives: We aimed to evaluate and compare the efficacy of intralesional injection of bevacizumab versus triamcinolone acetonide (TAC) in IH. Methods: Thirty patients with IH were included in this study, divided into two equal groups, and treated with intralesional injection; the first group by bevacizumab and the second group by TAC. The injections in both groups were given every 4 weeks for six sessions. Assessment of the clinical response was done by the hemangioma activity score (HAS) and visual analog scale (VAS). Results: Both treatment modalities gave similar initial improvement after three sessions. However, with continuing injection sessions, bevacizumab reached a response’s plateau and TAC gave better significant results after six injection sessions reading both HAS (p = .0017) and VAS (p ≤.001). Conclusion: Both intralesional injection of bevacizumab and TAC were safe and effective treatments in early proliferative IH after three sessions, however, TAC injection was significantly better than bevacizumab after six sessions.http://dx.doi.org/10.1080/09546634.2019.1590521infantile hemangiomabevacizumabtriamcinolone acetonide |
| spellingShingle | Hanan H. Sabry Neveen E. Sorour Essam M. Akl Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma Journal of Dermatological Treatment infantile hemangioma bevacizumab triamcinolone acetonide |
| title | Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma |
| title_full | Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma |
| title_fullStr | Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma |
| title_full_unstemmed | Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma |
| title_short | Intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma |
| title_sort | intralesional injection of bevacizumab versus triamcinolone acetonide in infantile hemangioma |
| topic | infantile hemangioma bevacizumab triamcinolone acetonide |
| url | http://dx.doi.org/10.1080/09546634.2019.1590521 |
| work_keys_str_mv | AT hananhsabry intralesionalinjectionofbevacizumabversustriamcinoloneacetonideininfantilehemangioma AT neveenesorour intralesionalinjectionofbevacizumabversustriamcinoloneacetonideininfantilehemangioma AT essammakl intralesionalinjectionofbevacizumabversustriamcinoloneacetonideininfantilehemangioma |